Navigation Links
Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Date:3/31/2009

Joint Venture to be funded by Cadila Pharmaceuticals and Revenues from Sales of Biogenerics; Deal Includes $11 Million Capital Investment in Novavax

ROCKVILLE, Md., March 31 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) announced today it has formed a joint venture with Cadila Pharmaceuticals Ltd. (Ahmedabad, India) to develop, manufacture and market vaccines, pharmaceuticals and diagnostic products in India. The joint venture will develop and commercialize Novavax's seasonal influenza virus-like-particle (VLP)-based vaccine candidate and Cadila's therapeutic vaccine candidates against cancer as well as its adjuvants, biogeneric and biological diagnostic products for the Indian territory. Novavax will also contribute technology to the joint venture for the development of several other VLP vaccine candidates against diseases of public health concern in that region, such as hepatitis E and Dengue fever. Cadila will contribute approximately $8 million over three years to support the joint venture operations. The joint venture will be responsible for clinical testing and registration of products that will be marketed and sold in India by the joint venture, which will be owned 80 percent by Cadila and 20 percent by Novavax once approval of India Foreign Investment Promotion Board is obtained. Novavax will have the right to negotiate license arrangements of certain vaccines developed by the joint venture for commercialization worldwide outside of India while also having rights to negotiate for other vaccines for commercialization in the US and several other territories outside India.

As part of this strategic alliance, pursuant to a stock purchase agreement dated March 31, 2009, a wholly-owned subsidiary of Cadila will purchase 12.5 million shares of Novavax's common stock at the market price of $0.88 per share, f
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
(Date:8/20/2014)... N.C. , Aug. 20, 2014 ... research services located in Raleigh, NC ... Bradford Evans as Vice President of Administration. ... Brad will oversee all corporate processes, including their ... joining Clintrax Global, Brad worked as an HR ...
(Date:8/20/2014)... in measuring vibrational motion of a single molecule with ... of a single molecule differs from the behaviour of ... at the University of California, Irvine, where post-doctoral researcher ... a visiting fellow under professor Vartkess A. Apkarian, whose ... lead by Professor Eric O. Potma. The results of ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014  Decision Resources Group ... , Russia , India ... approximately $1.6 billion in 2013, roughly equal to the size of ... forward, however, the BRIC market will experience much faster growth as ... the aging population. Other key findings from Decision Resources ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... and LEXINGTON, Massachusetts, August 25, 2011 Shire ... specialty biopharmaceutical company, today announced that the U.S. Food and ... (icatibant injection) for treatment of acute attacks of hereditary ... "Until now, HAE patients faced challenges gaining rapid ...
... CBI, a division of Advanstar Communications, is pleased ... Tufts Center for the Study of Drug Development and ... the keynote speaker at their Pharma/Bio Forum on Preclinical ... at the Hyatt Harborside in Boston, MA. Dr. Kaitin ...
... school science teachers will explore the nanotechnology field at ... build interest in science and engineering. ... of Engineering a $429,000 grant to fund "Innovations in ... Starting next summer, selected middle and high school ...
Cached Biology Technology:FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference 2University of Houston receives NSF grant for high school teachers program 2
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... second most common cause of childhood blindness in the ... earlier than or at 28 weeks gestational age. The ... the retina of the eye. ROP risk increases with ... Brigham and Women,s Hospital (BWH) suggests that the antioxidant, ...
... young researchers were named Pew Scholars in the Biomedical ... join a prestigious community that includes Nobel Prize winners, ... Research Award. "During these challenging budgetary ... harder for scientists to obtain, we are proud to ...
... heavy rain, the lid of Nepenthes gracilis ... shelter on its underside directly into the fluid-filled pitcher, ... Wednesday 13 June, in the journal PLoS ONE ... a source of nutrients, enabling them to colonise nutrient-poor ...
Cached Biology News:Antioxidant shown to reduce blindness risk in extremely premature babies 222 of America's most promising scientists selected as Pew Biomedical Scholars 222 of America's most promising scientists selected as Pew Biomedical Scholars 3Pitcher plant uses rain drops to capture prey 2
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
Biology Products: